Select Publications

Pharmacology

 

Pong AW, Ross J, Tyrlikova I, Giermek AJ, Kohli MP, Khan YA, Salgado RD, Klein P.  Epilepsy: Expert Opinion on Emerging Drugs in Phase 2/3 Clinical Trials.  Expert Opinion on Emerging Drugs, 2022, 27:1, 75-90, DOI: 10.1080/14728214.2022.2059464.

 

Pong AW, Xu KJ, Klein P. Recent advances in pharmacotherapy for epilepsy. Curr Opin Neurol. 2023 Apr 1;36(2):77-85. DOI: 10.1097/WCO.0000000000001144. Epub 2023 Feb 10. PMID: 36762638. 

 

Pong AW, Tyrlikova I, Giermek AJ, Klein P. Impact of regulatory safety warnings and restrictions on drug treatment of epilepsy. Expert Opin Drug Saf. 2023 Feb;22(2):111-114. DOI: 10.1080/14740338.2023.2188189. Epub 2023 Mar 9. PMID: 36881668. 

 

Pong AW, Klein P. Prevention of drug resistant epilepsy and developmental epileptic encephalopathy: preventative vigabatrin treatment in tuberous sclerosis complex and the case for fenfluramine treatment of children with newly diagnosed Dravet Syndrome.  OBM Genetics, 2024, 8:2.  DOI:10.21926/obm.genet.2402234.  Link: https://www.lidsen.com/journals/genetics .  ISSN 2577-5790. 

 

Depositaro-Cabacar DF, Peters J, Pong AW, Roth J, Rotenberg A, Riviello JJ, Takeoka M.  High-Dose Intravenous Levetiracetam for Acute Seizure Exacerbation in Children with Intractable Epilepsy.  Epilepsia, 2010;51:1319-22.

 

Obeid M, Pong AW.  Efficacy and tolerability of high oral doses of Levetiracetam in children with epilepsy.  Epilepsy Research, 2010;91:101-5.

 

Klein P, Tyrlikova I, Ross J, Ramos A, Pong AW.  Levetiracetam and Brivaracetam.  Wyllie's Treatment of Epilepsy Principles and Practice, 8th edition, Wolters Kluwer, 2024.

​

 

​

Genetics

 

Pal DK, Pong AW, Chung WK.  Genetic Evaluation and Genetic Counseling for Epilepsy. Nature Reviews Neurology, 2010;6:445-53.

 

Pong AW, Pal DK, Chung WK.  Developments in Molecular Genetic Diagnostics: an Update for the Epilepsy Specialist.  Pediatric Neurology, 2011;44:317-27.

 

Pong AW, Geary B, Engelstad K, Natarajan A, Yang H, De Vivo DC. Glucose Transporter Type I Deficiency Syndrome: epilepsy phenotypes and outcomes. Epilepsia, 2012 Sep:53(9):1503-10.

 

Pong AW, De Vivo DC.  Glucose Transporter Type I Deficiency Syndrome.  Inherited Metabolic Epilepsies, Demos Medical, 2013; 179-88.

 

Eksioglu Y, Pong AW, Takeoka M. A Novel Mutation in the Aristaless Domain of the ARX Gene Leads to Ohtahara Syndrome, Global Developmental Delay and Ambiguous Genitalia in Males and Neuropsychiatric Disorders in Females.  Epilepsia, 2011 May;52(5):984-92. 

 

Pong AW, Eksioglu YZ, Takeoka M. ARX mutations in females: an under-recognized cause of epilepsy and developmental delay.  Biology of Seizure Susceptibility in Developing Brain.  Progress in Epileptic Disorders, 6:65-74, 2008.

 

 

​

Original Book

 

Pong, Amanda W.  Finding Payton: An Odyssey Towards Seizure Freedom in Lennox-Gastaut Syndrome.  Self-Published, Amanda W. Pong, 2023.   

 

​

​

Invited Grand Rounds / Chaired Events 

                        

Harvard Epilepsy Grand Rounds (Speaker).  “Clinical Drug Trial and New Anti-Seizure Medications in Lennox-Gastaut Syndrome: Opportunities for Durable and Sustained Seizure Control.  Boston, MA, July 18, 2024.     

 

Epilepsy Awareness Day (Keynote Speaker). 12th Annual Epilepsy Awareness Day Conference.  Anaheim, CA, October 30-31, 2023. 

 

Clinical Trials and Research Symposium (Chair, Moderator). 11th and 12th Annual Epilepsy Awareness Day Conference.  Anaheim, CA, October 30-31, 2023 and November 18-19, 2024.